CA-CLOUDLINUX-INC
2.6.2021 14:26:12 CEST | Business Wire | Press release
CloudLinux Inc., the team behind creating the popular CloudLinux operating system used extensively in the hosting community, announces the release of CloudLinux OS Solo. This is a new step for the hosting market, a new low-cost operating system that optimizes Linux server and application performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005624/en/
Direct speech from CloudLinux Product team:
What was the motivation behind developing a new Operating System?
“Our starting point was clear. Based on research results, our clients overwhelmingly want the classic CloudLinux OS with VPS and VMs, which only a few users can then utilize. One main request is a robust set of CloudLinux features on one server at affordable prices. Consequently, we found hundreds of VPSs with five or fewer websites hosted by a single client, many of which use VMs for staging and production. Some clients want a stable OS with technical support that is secure and not open-sourced.”
CloudLinux OS Solo is a low-cost Linux OS for small businesses and any individual with just one hosting account which is maintained with 24/7 support. It is optimized for website and server performance, with features most needed to maintain online business stability.
What does the new CloudLinux OS Solo do? It detects server and website performance bottlenecks that can slow down customer business flow. There is also a substantial array of notifications and alerts that help users quickly detail server performance issues.
Moreover, the new OS focuses on domains' availability and responsiveness and has a PHP Slow Site analyzer that generates daily reports for the server administrator with information about the top slow PHP-based URLs for all domains. And PHP X-Ray identifying the slow CMS plugins, which ultimately speeds up the website. The new CloudLinux OS Solo also shows detailed information about database errors caused by slow queries, fixes code that causes slow functions, and slow external calls.
More features focused on website optimization will be available soon with the CloudLinux OS Solo. For example, single-click WordPress optimization will increase productivity, and together with Smart Advice, will help to improve website performance metrics, which is so important for online businesses.
Who will use CloudLinux OS Solo? Hosting providers who provide VPS and want to increase the upsell opportunities, product portfolio expansion, and a decrease in performance complaints. Small businesses and any individual with just one hosting account who want to speed up their online business and care about SEO metrics, value a fast and optimized website from a high-performed web server. CloudLinux OS Solo is fully automated (works out of the box), has 24/7 support from trusted vendor CloudLinux, and is compatible with all popular hosting software.
About CloudLinux Inc.
As an industry leader, CloudLinux persistently keeps up with server security issues that influence Linux server device stability and availability. Based in Palo Alto, California, the heart of Silicon Valley, CloudLinux develops a strengthened Linux distribution.
CloudLinux offers live security patching for all Linux kernels and extended support options for all distros. The robust Linux product offerings increase server security and software used by enterprises, service providers, governments, and universities worldwide.
To date, CloudLinux Inc. has over 500,000 product installations with more than 4,000 customers and partners globally. As a top provider of Linux-based software options, CloudLinux, prides itself on industry-leading customer service supported by technicians with 450 years of combined Linux experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005624/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom